← Back to headlines
Replimune Group stock reaches 52-week high
Oncology-focused biopharmaceutical company Replimune Group saw its shares surge to a 52-week peak of $15.72, driven by positive investor sentiment surrounding its clinical trial pipeline and recent corporate developments.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
